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Abstract
Background: After coronary stenting, the risk of developing restenosis is from 20 to 35 %. The aim of the present
study is to investigate the association of genetic variation in candidate genes in patients diagnosed with restenosis
in the Kazakh population.
Methods: Four hundred fifty-nine patients were recruited to the study; 91 patients were also diagnosed with
diabetes and were excluded from the sampling. DNA was extracted with the salting-out method. The patients
were genotyped for 53 single-nucleotide polymorphisms. Genotyping was performed on the QuantStudio 12K Flex
(Life Technologies). Differences in distribution of BMI score among different genotype groups were compared by
analysis of variance (ANOVA). Also, statistical analysis was performed using R and PLINK v.1.07. Haplotype frequencies
and LD measures were estimated by using the software Haploview 4.2.
Results: A logistic regression analysis found a significant difference in restenosis rates for different genotypes. FGB
(rs1800790) is significantly associated with restenosis after stenting (OR = 2.924, P = 2.3E−06, additive model) in the
Kazakh population. CD14 (rs2569190) showed a significant association in the additive (OR = 0.08033, P = 2.11E−09) and
dominant models (OR = 0.05359, P = 4.15E−11). NOS3 (rs1799983) was also highly associated with development of
restenosis after stenting in additive (OR = 20.05, P = 2.74 E−12) and recessive models (OR = 22.24, P = 6.811E−10).
Conclusions: Our results indicate that FGB (rs1800790), CD14 (rs2569190), and NOS3 (rs1799983) SNPs could be genetic
markers for development of restenosis in Kazakh population. Adjustment for potential confounder factor BMI gave
almost the same results.
Keywords: Coronary heart disease, Restenosis, SNP, Genotyping
Background
Coronary heart disease (CHD) is a disease characterized
by reduced blood supply to the heart muscle. Narrowing
of the coronary arterial lumen due to atherosclerosis is
the primary cause in 97–98 % of CHD cases. Coronary
heart disease has the highest rate of death and serious
complications among all forms of cardiovascular disease.
An estimated 17.5 million people died from cardiovascular
diseases in 2012, representing 31 % of all global deaths. Of
these deaths, an estimated 7.4 million were due to CHD
and 6.7 million were due to stroke [1]. It should be noted
that CHD usually affects the population aged between 35
and 65 years. In addition, CHD represents the most im-
portant cause of sudden cardiac deaths. Together with
cerebrovascular diseases, CHD accounts for 64 % of all
cardiovascular deaths [2].
According to the Ministry of Healthcare and Social
Development of the Republic of Kazakhstan prior to
year 2012, CHD morbidity has been constantly increas-
ing in 2009–2012 with exception of 2013 when a minor
decrease in the morbidity was observed [3]. In 2013,
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there were 59,799 new cases of CHD registered in
Kazakhstan and the morbidity rate reached 500.6 cases
per 100,000 population, compared to 445.6 cases in 2011
and 507.4 cases in 2012 [3].
Advances in medicine have led to the emergence of
novel methods of CHD treatment, such as angioplasty
or coronary stenting. The first use of coronary stenting
in clinical practice was in 1986 [4]. Primary percutaneous
coronary intervention (PCI) has become a well-established
strategy for patients with coronary heart disease [5]. Now-
adays, endovascular methods for the reestablishment of
coronary blood flow preserve the lives and health of hun-
dreds of thousands of people around the world. Neverthe-
less, there is a possibility that during the first 6 months to
1 year after successful coronary stenting, a symptomatic
relapse of angina may occur due to the development of re-
stenosis. Reoccurrence of stenosis is a major limitation to
the effectiveness of the stenting, and even the use of drug-
eluting stents does not solve the problem completely [6].
After coronary stenting, the restenosis rate is 20–30 %.
The use of second generation drug-eluting stents has re-
duced this rate, but the development of restenosis after
implantation remains a serious clinical problem [7].
Restenosis can occur for many different reasons. The
pathophysiological mechanisms of restenosis have not
yet been fully explained, but it is believed that those
mechanisms include inflammation, proliferation, and
matrix remodeling. Over the years, many predictive
clinical, biological, genetic, epigenetic, lesion-related, and
procedural risk factors for restenosis have been identified.
Those factors are useful in the risk stratification of pa-
tients and also contribute to our understanding of this
condition [8]. In this sense, the search for new predictor
factors in the development of restenosis is topical.
Currently, the genetic factors of restenosis have been
studied mostly in European populations. The ethnical
variability of genetic markers is well known, as shown in
the results of the GENetic DEterminants of Restenosis
(GENDER) study discussed in the article by Verschuren
et al. The GENDER databank contains the genotypic
data of 2,571,586 single-nucleotide polymorphism (SNPs)
from 295 cases with restenosis and 571 matched controls.
The set that included all 36 reported genes in the litera-
ture was indeed significantly associated with restenosis in
the GENDER study (P = 0.024). Subsequent analyses of
the individual genes demonstrated that this association
was determined by 6 of the 36 genes [9]. As a result of the
GENDER study, the selected SNPs have been associated
with the risk of developing restenosis in European
populations.
Based on literature review, candidate genes for resten-
osis were not studied or validated in Kazakh population.
That is why the purpose of the current study is to look
for associations of genetic variation in candidate genes
in patients diagnosed with restenosis after percutaneous
coronary intervention in the Kazakh population.
Methods
Study population
There were initially 459 patients with diagnosed CHD
recruited to the study. Of these patients, 91 were also
diagnosed with diabetes and were excluded from the
sampling, since several studies have shown that dia-
betes is an independent risk factor for restenosis and
may introduce bias to the interpretation of results [10].
Anthropometrical and biochemical characteristics were
gathered for the population sample comprising 368 patients
(299 males and 69 females). There were 99 case subjects,
those who manifested in-stent restenosis within 6 months
after stenting and 269 control subjects and those who did
not developed restenosis after stenting. The study protocol
was approved by the Ethics Committee of the National
Center for Biotechnology. All subjects were ethnic Kazakhs.
Genotyping
Whole blood samples of 368 patients (9 ml) were col-
lected into tubes containing 50 mmol/l ethylenediamine-
tetraacetic acid (disodium salt). DNA was extracted with
the salting-out method. [11]. Genotyping of the extended
panel of polymorphisms of candidate genes was performed
on the QuantStudio 12K Flex (Life Technologies). The
total reaction volume was 5 μl, containing 2.5 μl of 2×
OppenArray Real-time master mix, and 2.5 μl of DNA
concentration of 50 ng/μl. Temperature conditions were
10 min at 93 °C; cycling for 45 s at 93 °C, 13 s at 94 °C,
and 2.14 min at 53.5 °C for 50 cycles, followed by incuba-
tion at 25 °C for 2 min. Data analysis was performed using
the software package TaqMan Genotyper Software v.1.3.
Table 1 shows a panel of 53 SNPs used in the current
study. All SNPs were selected based on the results of the
GENDER study.
Statistical analysis
A pairwise correlation matrix was made to check for
multicollinearity between measured variables. A stepwise
regression was performed to evaluate significance of po-
tential confounders. A logistic regression analysis with
adjustment for potential confounder was used to test for
differences between statuses of restenosis according to
genotyping. Associations between each SNP and develop-
ment of the restenosis were tested according to three gen-
etic models: additive (cumulative effect of each additional
variant allele), dominant (homozygous wild-type vs. variant
allele-carrying genotype) and recessive (wild-type allele car-
rying genotype vs. homozygous variant genotype). Every
SNP that reached statistically significant level of P < 0.0001
were reported. Significant SNPs were further annotated
using RegulomeDB that harbors information for known
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and predicted regulatory elements [12]. Annotation of func-
tional variation in personal genomes using RegulomeDB.
Additionally, a differences in distribution of BMI score
among different genotype groups were compared by
one-way analysis of variance (one-way ANOVA). For
ANOVA test a default threshold of 0.05 was used to report
significance. Statistical analysis was performed using R
and PLINK [13, 14].
LD statistical analysis was performed using Haploview
4.2. For block generations, Hardy-Weinberg P value
cutoff 0.001 was used [15]. We ignored SNPs that minor
allele frequencies (MAF) of less than 0.001. For block
generations, the confidence intervals default algorithm
was used.
Results
A total of 368 patients participated in the study. Body
mass index (BMI), the blood levels of cholesterol, low-
density lipoproteins (LDL), and high-density lipoproteins
(HDL) were recorded for every patient at the time of
participation. Table 2 shows summary statistics of the
measured variables.
Anthropometrical and measured biochemical charac-
teristics for potential confounders were evaluated before
performing a test for association between genotype
distribution and restenosis status. The distributions of
the measured traits fitted the normality assumption
and were included in the analysis as is without any
transformation. Construction of the correlation matrix
revealed that in our dataset, cholesterol and LDL are
Table 1 Description of SNPs included in the study
Gene Polymorphism Locus
Adrenergic beta-2-receptor (ADRB2) rs1042713 5q31–q32
Advanced glycosylation end
product-specific receptor (AGER)
rs2070600 6p21.3
Advanced glycosylation end
product-specific receptor (AGER)
rs1800624 6p21.3
Angiotensin II receptor, type 1 (AGTR1) rs5186 3q24
Angiotensin II receptor, type 1 (AGTR1) rs5182 3q24
Butyrylcholinesterase (BCHE) rs1803274 3q26.1–q26.2
Chemokine (C–C motif) ligand
11 (CCL11)
rs4795895 17q21.1–q21.2
Cluster of differentiation 14 (CD14) rs2569190 5q31.1
Cyclin-dependent kinase inhibitor 1B
(p27, Kip1, CDKN1B)
rs34330 12p13.1–p12
Collagen, type III, alpha 1 (Col3A1) rs1800255 2q31
Colony stimulating factor 2 (CSF2) rs25882 5q31.1
Chemokine (C-X3-C motif) receptor 1
(CX3CR1)
rs3732379 3p21.3
Cytochrome b-245, alpha polypeptide
(CYBA)
rs4673 16q24
Cytochrome P450, family2, subfamily C,
polypeptide 19 (CYP2C19)
rs12248560 10q24
Fibrinogen beta chain (FGB) rs1800790 4q28
Fibrinogen beta chain (FGB) rs1044291 4q28
Coagulation factor V (F5) rs6025 1q23
Glutathione peroxidase 1 (GPX1) rs8179164 3p21.3
Integrin, beta 2 (ITGB2) rs235326 21q22.3
Lipoprotein lipase (LPL) rs328 8p22
Matrix metallopeptidase 12 (MMP12) rs12808148 11q22.3
Matrix metallopeptidase 12 (MMP12) rs17099726 20q11.2–q13.1
Matrix metallopeptidase 12 (MMP12) rs2276109 20q11.2–q13.1
Methylenetetrahydrofolate reductase
(NAD(P)H) MTHFR)
rs1801133 1p36.3
Nitric oxide synthase 3 (NOS3) rs2070744 7q36
Nitric oxide synthase 3 (NOS3) rs1799983 7q36
K(lysine) acetyltransferase2B
(KAT2B, PCAF)
rs2948080 3p24
K(lysine) acetyltransferase2B
(KAT2B, PCAF)
rs6776870 3p24
K(lysine) acetyltransferase2B
(KAT2B, PCAF)
rs2929404 3p24
K(lysine) acetyltransferase2B
(KAT2B, PCAF)
rs17796904 3p24
Peroxisome proliferator-activated
receptor gamma (PPARG)
rs3856806 3p25
C-ros oncogene1, receptor tyrosine
kinase (ROS1)
rs529038 6q22
Thrombomodulin (THBD) rs1042579 20p11.2
Thrombospondin 4 (THBS4) rs1866389 5q13
Thrombopoietin (THPO) rs6141 3q27
Table 1 Description of SNPs included in the study (Continued)
Tumor protein p53 (TP53) rs1042522 17p13.1
Transferrin (TF) rs1799899 3p
Uncoupling protein 3 (UCP3) rs1800849 11q13.4
Vitamin D receptor (VDR) rs11568820 12q13.11
Vitamin D receptor (VDR) rs11574027 12q13.11
Vitamin D receptor (VDR) rs11574077 12q13.11
Tumor necrosis factor α (TNFα) rs1800629 6p21.3
Tumor necrosis factor α (TNFα) rs361525 6p21.3
Interleukin 1 receptor antagonist (IL1RN) rs419598 2q14.2
Interleukin 1α (IL1A) rs1800587 2q12–q21
Interleukin 1 β (IL1B) rs1143627 2q13–q21
Interleukin 4 (IL4) rs2243250 5q23–31
Interleukin 6 (IL6) rs1800796 7p21
Interleukin 8 (IL8) rs 4073 4q12–q13
Interleukin 10 (IL10) rs1800871 1q31–q32
Interleukin 10 (IL10) rs1800872 1q31–q32
Interleukin 10 (IL10) rs1800896 1q31–q32
Interleukin 10 (IL10) rs3024498 1q31–q32
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highly correlated with each other (Table 3). In order to
avoid multicollinearity, cholesterol was excluded from
further analysis.
The remaining traits were used to build a statistical
model that predicts the development of restenosis as a
main outcome. Age, LDL, and HDL contribute insignifi-
cantly to restenosis variability in our dataset based on
the results from stepwise regression analysis. The final
statistical model included BMI as a single confounding
factor that may affect the association between genotype
and restenosis status.
There were 368 patients available to collect whole
blood for further genetic analysis. After applying quality
control filters, the final dataset contained 268 patients
with genotype information for 48 SNPs. Four SNPs were
excluded based on the Hardy Weinberg equilibrium test
(P ≤ 0.001). One SNP was excluded because of its low
genotyping rate.
SNPs that reached a significant level P < 0.0001 were
reported. The results from logistic regression revealed
that FGB (rs1800790) SNP was associated with restenosis
after stenting. Notably that homozygous A allele carriers
of the rs1800790 SNP are 24 times less likely to develop
restenosis after stenting compared to other allele carries.
CD14 (rs2569190) SNP showed highly significant correl-
ation development of restenosis. Based on results, carrying
homozygous G allele is a risk factor for development of re-
stenosis. Finally, a missense mutation rs1799983 SNP
mapped to NOS3 was also highly associated with the de-
velopment of restenosis after stenting. Both additive and
recessive models showed similar results, suggesting that
carrying additional G allele for rs1799983 SNP is a pro-
tective factor against developing restenosis. Summary
for the results of logistic regression analysis is shown in
Table 4.
Association of genotype of the candidate genes 53 SNP
with the restenosis was examined with one-way ANOVA
by comparing the mean scores of BMI to the genotype.
According to ANOVA, BMI distribution had significant
differences with genotypes of rs6025 SNP in coagulation
factor V also known as F5 (P = 0.00643) in control group.
rs419598 SNP mapped to IL1RN was positively associated
with BMI in the control group (P = 0.0299). Finally,
rs4795895 SNPs mapped to CCL11 gene showed sig-
nificant differences with BMI in group of patients (P =
0.012).Genotypes of other SNPs were not significantly
different.
Using Haploview 4.2 software, LD statistics results for
the Kazakh population were obtained (Fig. 1) (HW P cut-
off, 0.001; MAF, 0.001). As a result, two haplotype blocks
were defined: one block consisting of two SNPs, i.e.,
rs5182 and rs5186 (block 1, chromosome 3); one block
consisting of two SNPs, i.e., rs1800871 and rs1800896
(block 2, chromosome 1). The haplotype frequencies in
the studied population are presented in Table 5. Haplotype
CC (rs5182-rs5186, block 1) was associated with the risk
of developing restenosis (OR 2.17; 95 % CI; 1.33–3.53,
P = 0.002) and the haplotype GC (rs1800871-rs1800896,
block 2) was associated with restenosis (OR 1.51; CI,
1.01–2.26, P = 0.04).
Discussion
The present study included Kazakhs that are Turkic
people of the northern parts of Central Asia (largely
Kazakhstan). From the historic point of view and be-
cause of scarce genetic data, it was concluded that
Kazakh population was formed as a result of admixture of
the European and Asian populations [16]. Case and con-
trols were diagnosed with CHD. BMI was increased in
both groups. Our results showed that BMI is a single con-
founding factor that may affect the association between
genotype and restenosis status. In turn, genotype polymor-
phisms of F5, IL1RN, CCL11 genes significantly influence
on increased body mass index.
The present study focuses on 48 SNPs in 36 candidate
genes that were previously reported as genetic risk factors
for restenosis. Association of hemostatic gene polymor-
phisms with restenosis after coronary stent placement was
the first genetic risk to be described [17, 18]. The associ-
ation of selected SNPs in inflammation-related genes with
restenosis is also well documented [19–21]. In addition, a
number of candidate genes in the renin-angiotensin hor-
mone system and the endothelial nitric oxide synthase
(eNOS, Glu298Aps and −786T\C) are also involved in this
process [22–24]. New molecular markers of restenosis
are constantly emerging. For example, in a recent study,
SNPs in VDR (vitamin D-dependent receptor) gene were
Table 2 Anthropometrical and biochemical characteristics of
the population sample (n = 368)
Restenosis (case/control) 99/269
Gender (male/female) 299/69
Age (years) 58.61 ± 11.67
BMI (kg/m2) 28.35 ± 4.53
Cholesterol (mmol/l) 4.93 ± 1.24
LDL (mmol/l) 3.05 ± 1.18
HDL (mmol/l) 1.24 ± 0.63
BMI body mass index, LDL low-density lipoproteins, HDL high-density lipoproteins
Table 3 Pairwise correlation matrix of measured variables
BMI HDL LDL Cho Age
Age −0.072 −0.067 −0.061 −0.081 1
Cho 0.402 0.364 0.739 1
LDL 0.322 0.492 1
HDL 0.163 1
BMI 1
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considered as risk markers of restenosis [25]. Fragoso et al.
reported that transforming growth factor-1β (rs1800469)
was associated with the risk of developing restenosis after
coronary stenting in Mexican patients [26]. This SNP was
not investigated in our study.
Our study has revealed that blood coagulation fibrino-
gen factor I (FGB), monocyte differentiation antigen CD14
(CD14), and nitric oxide synthase 3 (NOS3) genes are
among the factors associated with the risk of restenosis in
the studied population.
Monocytes play a central role in restenosis after balloon
angioplasty and stent implantation. Monocytes migrate
into the damaged area either as a direct response or
through the release of platelet-derived factors. Activated
monocytes release large amounts of proinflammatory
cytokines, which cause vasoconstriction and non-specific
recruitment, proliferation, and activation of other cells in-
cluding vascular smooth muscle cells in the vascular wall.
The activation of monocytes/macrophages, endothelial
cells, and smooth muscle cells mediated by CD14 and/or
CD14 may play an important role in the restenosis
processes [27].
Functional C(-260)→T polymorphism in the promoter
of the CD14 gene has been reported to be associated
with CHD but data have yielded conflicting results. In the
meta-analysis of Zhang et al., TT genotype is associated
with ischemic heart disease in the East Asian population
but not in the European or Indian populations [28]. Two
previous studies have investigated the role of CD14 in the
development of restenosis, one being a prospective study
by Zee et al. [29] in 779 patients and the other being a
prospective study by Shimada et al. [27] in 129 Japanese
patients. They found the −260T/T genotype to be a
risk factor for restenosis. But the GENDER study found
that T allele was not associated with restenosis in the
European population [9]. Also, it was showed that the
CD14+CD16+CX3CR1+monocytes might have a role
in-stent restenosis following coronary implantation of
bare-metal stents in patients with acute myocardial in-
farction [30].
The results of our study have revealed that CD14 pro-
moter polymorphism remained statistically significant in
the additive (OR = 0.08033, P = 2.11E−09) and dominant
models (OR = 0.05359, P = 4.15E−11). Therefore, the T
allele at position −260 of CD14 gene is a risk allele for
restenosis in Kazakh population. Population stratification
based on ethnicities may lead to inconsistency, especially
when both allele frequencies and incidence rates of the
diseases vary across ethnic groups.
Fibrinogen (factor I) is a glycoprotein synthesized by
the liver. It consists of three polypeptides Aα, Bβ, and γ
coded by the alpha (FGA), beta (FGB), and gamma (FGG)
genes, respectively. Fibrinogen is an important component
of the coagulation cascade and a major determinant of
Table 4 Results from logistic regression analysis
Boldsnp that also had functional effect, red P values unadjusted, green P values adjusted for BMI
Fig. 1 LD SNP plot. The LD is displayed according to standard color schemes, with bright red for very strong LD (LOD > 2, D’ = 1),
light red (LOD > 2, D’ < 1) and blue (LOD < 2, D’ = 1) for intermediate LD, and white (LOD < 2, D’ < 1) for no LD
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blood viscosity and platelet aggregation [31]. Polymor-
phisms of FGB was shown to be associated with coronary
heart disease [32, 33]. In a study by Völzke in 2004, there
was no association between the β-fibrinogen −455G/A
and the risk of restenosis after PTCA or recurrent re-
stenosis after re-PTCA [34]. In the GENDER study, a
multicenter prospective study, the association of gene
polymorphism FGB −455G>A(rs1800790) with the risk
of restenosis was not found in the European population
[9]. In the study by Oguri in 2007, the association of
FGB −455G>A (rs1800790) with restenosis was shown
in the Japanese population [35]. Our results suggest that
genotype FGB −455G>A (rs1800790) is significantly asso-
ciated with restenosis after stenting (OR = 2.924, P = 2.3E
−06, additive model) in the Kazakh population. Interest-
ingly that the same SNP in dominant model gave close P
value, but much higher OR = 24.36, suggesting that allele
A is a recessive protective factor against development of
restenosis. Thus, it can be concluded that the relationship
between genetic polymorphisms of FGB −455G>A
(rs1800790) and the development of restenosis is not uni-
versal between different ethnic groups. It is also interesting
to observe that Japanese and Kazakhs are alike in turns of
effect from polymorphisms of FGB −455G>A (rs1800790).
Nitric oxide synthase 3 (NOS3) locates at chromosome
7q36, and it encodes endothelial nitric oxide synthase
(eNOS), which can generate nitric oxide (NO) in endo-
thelial cells. Endothelial NO is a key determinant of vas-
cular homeostasis, and it can also participate in vascular
repair. Dysfunction of any of these processes may result
in atherosclerotic and thrombotic diseases [36–38]. The
association between several polymorphisms of the NOS3
gene and CAD and restenosis risks has been previously
studied [39–41]. In the meta-analysis by Zhang et al., 18
case-control studies with 2994 cases and 3130 controls,
including 13 studies of East-Asia descendents, 5 studies
of non-East-Asian descendents indicated that eNOS
894G/T polymorphism may play an important role in
CHD development among Asian population [42]. In 2010,
Li et al. performed a meta-analysis involving 20 studies re-
lating non-Asian population and 3 studies relating Asian
population and found significant association of T allele in
eNOS 894G/T with CHD in non-Asian population [43].
Other studies showed that homozygosity of Glu298Asp
and 786T/C polymorphisms of the NOS3 gene repre-
sented an independent risk factor for in-stent restenosis,
and the 894G/T polymorphism of NOS3 gene was associ-
ated with an increased risk of death and/or myocardial in-
farction within 1 year after stent placement [24, 44, 45].
Shuvalova et al. showed that minor allele of polymorphism
298G/T of the eNOS gene (rs1799983) is associated with
an increased risk of in-stent restenosis [46].
A number of polymorphisms have been identified in
the NOS3 gene among which two polymorphisms in the
promoter region (−786C/T), and one in the exon (894G/T
or Glu298Asp) was studied. Only one of these polymor-
phisms NOS3 (rs1799983) has been found to be signifi-
cantly associated with restenosis in our study OR = 20.05,
P = 2.74E−12 in additive and OR= 22.24, P = 6.81E−10 in
recessive models. Thus, the present results demonstrated
that there might be a significant association between the
NOS3 polymorphism (rs1799983) and restenosis after PCI
in the Kazakh population.
In the linkage disequilibrium analysis, AGTR1 risk
(CC) haplotype and IL10 (GC) for developing restenosis
were detected in our study. Su et al. studied 16 AGTR1
polymorphisms. Based on the linkage disequilibrium
pattern among these SNPs, six polymorphisms were se-
lected as haplotype tagging SNPs and further were ge-
notyped. SNP analyses indicated that GTC haplotype
(rs275650, rs2276736, rs5182) associated with the risk
of developing myocardial infarction [47]. Koch et al. investi-
gated the possibility that single-nucleotide polymorphisms
of the genes encoding TNF (_863C/A, _308G/A), LT-a
(252G/A), and IL10 (_1082G/A, _819C/T, and _592C/A)
are associated with the incidence of restenosis, death, or
myocardial infarction (MI) after coronary stenting [48].
With regard to the IL10 polymorphisms, they observed
three different haplotypes, _1082G/_819C/_592C (GCC),
ACC, and ATA, with relative frequencies of 0.45, 0.29, and
0.26, respectively. Koch et al. have not detected a significant
correlation between restenosis and the frequency of the
Table 5 Frequencies (%) of AGTR haplotypes [rs5182(573C>T), rs5186 (1166A>C)] and IL10 haplotypes [rs1800871(−819 C>T), and
rs1800896 (−1082 A>G)] in patient with and without restenosis
With restenosis (n = 99) Without restenosis (n = 269) OR 95 % CI P value
Locus Haplotype Hf Hf
Block1 TA 0.634 0.669 – – NS
rs5182|rs5186 CA 0.162 0.221 – – NS
573C>T|1166A>C CC 0.205 0.110 2.17 1.33–3.53 0.002
Block 2 AT 0.455 0.493 – – NS
rs1800871|rs1800896 GC 0.340 0.238 1.51 1.01–2.26 0.04
819 C>T|−1082 A>G GT 0.198 0.266 – – NS
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haplotypes [48]. But in our study, it was identified that GC
haplotype of IL10 (819 C>T, −1082 A>G) was associated
with restenosis. Thus, individuals with the risk haplotype
have compromised function of inflammatory reactions.
Conclusion
In conclusion, the present study examined the association
between 48 SNPs and restenosis in the Kazakh population.
Our results indicate that BMI is a single confounding fac-
tor and FGB (rs1800790), CD14 (rs2569190), and NOS3
(rs1799983). SNPs could be genetic markers for the devel-
opment of restenosis in the Kazakh population. Genotyp-
ing of these polymorphisms may be used in predicting the
risk of restenosis in the Kazakh population.
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